share_log

Elevai Labs | 8-K: Current report

Elevai Labs | 8-K: Current report

Elevai Labs | 8-K：重大事件
美股SEC公告 ·  2024/10/25 05:12

Moomoo AI 已提取核心信息

Elevai Biosciences, a subsidiary of Elevai Labs, has entered into a Master Services Agreement (MSA) with KCRN Research on October 21, 2024, to support the development and submission of an Investigational New Drug (IND) application for EL-22, targeting obesity and muscle loss preservation treatment.The agreement outlines a three-phase approach: Phase 1 involves submitting a pre-IND meeting request to FDA, Phase 2 focuses on preparing the pre-IND package if the meeting is granted, and Phase 3 covers the actual pre-IND meeting attendance. The collaboration specifically involves EL-22, a recombinant bacterium engineered with a modified human myostatin gene.The MSA has an initial term of three years with automatic one-year renewals thereafter. Either party can terminate work orders with 30 days' notice, and the agreement includes standard termination clauses for material breaches or insolvency. KCRN will receive compensation based on contingent events at each phase.
Elevai Biosciences, a subsidiary of Elevai Labs, has entered into a Master Services Agreement (MSA) with KCRN Research on October 21, 2024, to support the development and submission of an Investigational New Drug (IND) application for EL-22, targeting obesity and muscle loss preservation treatment.The agreement outlines a three-phase approach: Phase 1 involves submitting a pre-IND meeting request to FDA, Phase 2 focuses on preparing the pre-IND package if the meeting is granted, and Phase 3 covers the actual pre-IND meeting attendance. The collaboration specifically involves EL-22, a recombinant bacterium engineered with a modified human myostatin gene.The MSA has an initial term of three years with automatic one-year renewals thereafter. Either party can terminate work orders with 30 days' notice, and the agreement includes standard termination clauses for material breaches or insolvency. KCRN will receive compensation based on contingent events at each phase.
Elevai Biosciences是Elevai Labs的子公司，于2024年10月21日与KCRN Research签署了一份《主服务协议》（MSA），旨在支持开发和提交针对EL-22的临床新药（IND）申请，目标是治疗肥胖和肌肉流失保护。协议概述了三期方法：第一期涉及向FDA提交预IND会议请求，第二期专注于准备预IND材料（如果会议获得批准），第三期涵盖实际的预IND会议出席。该合作特别涉及EL-22，这是一种经过改造的人类肌肉抑制素基因的重组细菌。MSA的初始期限为三年，之后自动续期一年。任何一方均可提前30天通知终止工作订单，协议还包括对于重大违约或破产的标准终止条款。KCRN将在每个阶段根据预定事件获得补偿。
Elevai Biosciences是Elevai Labs的子公司，于2024年10月21日与KCRN Research签署了一份《主服务协议》（MSA），旨在支持开发和提交针对EL-22的临床新药（IND）申请，目标是治疗肥胖和肌肉流失保护。协议概述了三期方法：第一期涉及向FDA提交预IND会议请求，第二期专注于准备预IND材料（如果会议获得批准），第三期涵盖实际的预IND会议出席。该合作特别涉及EL-22，这是一种经过改造的人类肌肉抑制素基因的重组细菌。MSA的初始期限为三年，之后自动续期一年。任何一方均可提前30天通知终止工作订单，协议还包括对于重大违约或破产的标准终止条款。KCRN将在每个阶段根据预定事件获得补偿。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Nutriband
    NTRB
    -- 7.340
    Eterna Therapeutics
    ERNA
    -- 0.635
    Tonix Pharmaceuticals
    TNXP
    -- 0.3190
    ImmunoPrecise Antibodies
    IPA
    -- 0.645
    Sonnet BioTherapeutic
    SONN
    -- 2.0000
    解锁完整榜单
    热门中概股
    追踪最热门的中概股实时资讯。